½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1308765

ÅÂ¾Æ ¸ð´ÏÅ͸µ ½ÃÀå ¿¹Ãø(-2030³â) : Á¦Ç°º°, Æ÷Åͺô¸®Æ¼º°, ¹æ¹ýº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¼¼°è ºÐ¼®

Fetal Monitoring Market Forecasts to 2030 - Global Analysis By Product, Portability, Method, Application, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 175+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ ÅÂ¾Æ ¸ð´ÏÅ͸µ ½ÃÀåÀº 2023³â¿¡ 28¾ï 9,000¸¸ ´Þ·¯¸¦ Â÷ÁöÇÏ°í ¿¹Ãø ±â°£ Áß CAGR 8.02%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 49¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

ÅÂ¾Æ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀº »ê¸ðÀÇ ÁøÅë°ú žÆÀÇ ¿òÁ÷ÀÓ, ½É¹Ú¼ö¸¦ ¸ð´ÏÅ͸µÇÏ´Â Áø´Ü ÅøÀÔ´Ï´Ù. ºÐ¸¸ Áß Àڱà ¼öÃàÀ» ¸ð´ÏÅ͸µÇÏ´Â °£´ÜÇÑ ÀåºñÀÔ´Ï´Ù. ÁַΠžÆÀÇ °Ç°­ »óÅÂ¿Í ÁøÅëÀÇ ÁøÇà »óȲÀ» ¸ð´ÏÅ͸µÇÕ´Ï´Ù. ÀÇÇÐ ¿ë¾î·Î´Â ¾ÈÀüÇÑ Ãâ»êÀ» º¸ÀåÇϱâ À§ÇØ Å¾Ƹ¦ °Ë»çÇÏ´Â ÀÇ·á ÀýÂ÷·Î Á¤Àǵ˴ϴÙ.

¹Ì±¹»êºÎÀΰúÇÐȸ(ACOG)¿¡ µû¸£¸é »êºÎÀΰú Àü¹® ¼ö¿ä´Â 2030³â±îÁö 50,850¸í¿¡¼­ 52,660¸í(4%)À¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¿ªÇÐ :

ÃËÁø¿äÀÎ

Á¶»ê °Ç¼ö Áõ°¡

Á¶»êÀº °íÇ÷¾Ð, ºÐ¸¸ Àü¸· ÆÄ¿­ÀÇ Àå±âÈ­, ºÐ¸¸ Àü ÃâÇ÷, ´ÙÅ ÀÓ½Å, º¸Á¶»ý½Ä¼ú, ªÀº ÀڱðæºÎ, ¿ä·Î°¨¿°(UTI), ÀüÄ¡ÅÂ¹Ý µî ´Ù¾çÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ Á¡Á¡ ´õ ÈçÇØÁö°í ÀÖ½À´Ï´Ù. Á¶»êÀÌ º¸ÆíÈ­µÊ¿¡ µû¶ó ÷´Ü ÀÇ·á ±â¼úÀÌ ÅÂ¾Æ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ¿¡ ÅëÇյǰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¾ïÁ¦¿äÀÎ

ÀçÈ°¿ë Á¦Ç° °¡¿ë¼º

Àç»ç¿ëÇ°ÀÇ °¡¿ë¼ºÀÌ ½ÃÀå È®´ëÀÇ ÁÖ¿ä À庮À¸·Î ÀÛ¿ëÇÏ°í ÀÖ½À´Ï´Ù. °¡°Ý¿¡ ¹Î°¨ÇÑ ½ÃÀåÀÎ °³¹ßµµ»ó±¹¿¡¼­´Â ¸¹Àº Áß¼ÒÇü º´¿øÀÌ ºñ¿ë È¿À²¼ºÀ» À§ÇØ ¸®ÆÛºê ½Ã½ºÅÛÀ» ¼±ÅÃÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¸®ÆÛºê Á¦Ç°Àº ¸ðµÎ »õ Á¦Ç°°ú µ¿ÀÏÇÑ ±â´ÉÀ» °¡Áö°í ÀÖÁö¸¸ °¡°ÝÀÌ Àú·ÅÇÕ´Ï´Ù. ÀÌ ¹®Á¦´Â ½ÃÀå¿¡¼­ ºê·£µå ÅÂ¾Æ ¸ð´ÏÅ͸µ Á¦Ç°À» ÆǸÅÇÏ´Â ±â¾÷ÀÇ ¸ÅÃâÀ» ¾ÇÈ­½Ãų °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

±âȸ :

Á¤ºÎ ±¸»ó Áõ°¡

ÅÂ¾Æ °Ç°­¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇÑ Á¤ºÎ ¹× ºñÁ¤ºÎ ±¸»ó Áõ°¡°¡ ½ÃÀåÀ» ÁÖµµÇÏ°í ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Áß¿äÇÑ ¿ä¼Ò´Â Èıâ ÀÓ½Å, ´ÙÅ ÀӽŠ¹× Á¶»ê »ç·Ê Áõ°¡ÀÔ´Ï´Ù. ¶ÇÇÑ ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È­¿Í ÇコÄɾ ´ëÇÑ ÀÎÇÁ¶ó ÁöÃâ Áõ°¡´Â »ê¾÷ È®ÀåÀ» ´õ¿í °¡¼ÓÈ­ÇÏ´Â ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇÏ°í ÀÖ½À´Ï´Ù.

À§Çù

¼÷·ÃµÈ ÀÇ·á Àü¹®°¡ ºÎÁ·

»êºÎÀΰú, »êºÎÀΰú ¹× ±âŸ ¿¹¹æ ¹× »ý½Ä ÀÇ·á Àü¹®°¡´Â ÁÖ·Î ¿©¼º °Ç°­¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖÁö¸¸ °ø±ÞÀÌ Á¦ÇѵǾî ÀÖ½À´Ï´Ù. ÀÌ´Â »êºÎÀΰú ¹× »êºÎÀΰúÀÇ ³ë·ÂÀÌ °íÀ§Çè ÀӽŰú ¾î·Á¿î ºÎÀΰú ÁúȯÀÇ °ü¸® ¹× ¿Ü°úÀû Ä¡·á¿¡ Á¡Á¡ ´õ ÁýÁßµÉ ¼ö ÀÖÀ½À» ½Ã»çÇÕ´Ï´Ù. ±×·¯³ª ÅÂ¾Æ ¸ð´ÏÅ͸µ ÀåºñÀÇ °íºñ¿ë ÁöÃâÀº ½ÃÀå È®´ë¸¦ Áö¿¬½Ãų °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

COVID-19ÀÇ ¿µÇâ :

ÅÂ¾Æ ¸ð´ÏÅ͸µÀº COVID-19 ¹ß»ý°ú ±×¿¡ µû¸¥ Æó¼â Á¶Ä¡·Î ÀÎÇØ ¿µÇâÀ» ¹ÞÀº »ç¾÷ Áß ÇϳªÀÔ´Ï´Ù. ¾ÈÀü»óÀÇ ÀÌÀ¯·Î Ä¡·á°¡ ¿¬±âµÇ°Å³ª ÀÏÁ¤ÀÌ º¯°æµÇ¸é¼­ ÆÒµ¥¹Í ±â°£ Áß ÀÔ¿ø ȯÀÚ ¼ö°¡ °¨¼ÒÇß°í, ÀÌ´Â ÅÂ¾Æ ¸ð´ÏÅ͸µ ½Ã¼ú °Ç¼ö °¨¼Ò¿¡ ¿µÇâÀ» ¹ÌÃƽÀ´Ï´Ù. ÀÌ·¯ÇÑ ¿¬±â¿¡ ¾Õ¼­ ȯÀÚÀÇ º´·ÂÀ» Á¾ÇÕÀûÀ¸·Î °ËÅäÇÏ°í, °¡´ÉÇÑ °æ¿ì ÀÔ¿ø Áß ³ëÃâ À§ÇèÀ» ÁÙÀ̱â À§ÇØ ÅÂ¾Æ ¸ð´ÏÅ͸µ ½Ã±â¸¦ º¯°æÇß½À´Ï´Ù. µû¶ó¼­ Àü¿°º´Àº ÀÌ ºÎ¹®¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.

¿¹Ãø±â°£ Áß ÃÊÀ½ÆÄ Áø´Ü±â±â ºÐ¾ß°¡ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»ó :

ÃÊÀ½ÆÄ Àåºñ ºÎ¹®Àº À¯¸®ÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÃÊÀ½ÆÄ Àåºñ´Â Àå±â ³»ºÎ¸¦ °Ë»çÇϱâ À§ÇØ À̹ÌÁö¸¦ »ý¼ºÇÕ´Ï´Ù. °íÁÖÆÄ À½ÆÄ°¡ Àåºñ¿¡¼­ ¹æÃâµÇ¾î ½Åü ±¸Á¶°¡ ¹Ý»çµË´Ï´Ù. ÄÄÇ»ÅÍ°¡ ÀÌ Æĵ¿À» °¨ÁöÇÏ¿© À̹ÌÁö¸¦ »ý¼ºÇϴµ¥, ¿¢½º·¹À̳ª ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ(CT)°ú ´Þ¸® ÀÌ Áø´ÜÀº Àü¸®¹æ»ç¼±À» »ç¿ëÇÏÁö ¾Ê½À´Ï´Ù. ÀÌ À̹ÌÁö´Â žƸ¦ ¸ð´ÏÅ͸µÇÏ°í ´Ù¾çÇÑ Áúº´°ú Áõ»óÀÇ Áø´Ü ¹× Ä¡·á °èȹÀ» ¼¼¿ì´Â µ¥ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

º´¿ø ºÎ¹®Àº ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»ó

º´¿ø ºÎ¹®Àº º´¿øÀÌ Á¦°øÇÏ´Â ÅÂ¾Æ ¸ð´ÏÅ͸µ ÀåºñÀÇ °­È­¿Í ¼÷·ÃµÈ ÀÇ»ç ¹× ÀÎÇÁ¶óÀÇ °¡¿ë¼ºÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ CAGR ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¸ÅÃâ Áõ°¡´Â º´¿ø¿¡ ¼³Ä¡µÈ ÅÂ¾Æ ¸ð´ÏÅ͸µ ÀåºñÀÇ ¼ö¿Í ÅÂ¾Æ ¸ð´ÏÅ͸µÀ» À§ÇØ º´¿øÀ» ¹æ¹®Çϴ ȯÀÚ ¼ö ¸ðµÎ¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.

°¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª

ºÏ¹Ì´Â ¿¹Ãø ±â°£ Áß °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ¸¹Àº ±¹°¡¿¡¼­ Á¤ºÎ°¡ ÀÇ·á ¿¬±¸¸¦ À§ÇÑ ¼Ò±Ô¸ð ¼³¸³¿¡ ´ëÇÑ ±ÇÇÑÀ» ºÎ¿©ÇÏ°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ÀÇ·á ÀÎÇÁ¶ó°¡ ³«ÈÄµÈ ±¹°¡ÀÇ ³óÃÌ Áö¿ª¿¡¼­ ÀÇ·á ¼­ºñ½º¸¦ È®´ëÇϱâ À§ÇØ ¹Î°£ ºñ¿µ¸® ´Üü¿¡ º¸Á¶±ÝÀ» Áö±ÞÇÏ´Â µî »êºÎÀΰú ½Ã¼³ °³¼±¿¡ ´ëÇÑ Á¤ºÎ Áö¿øÀÌ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª :

¾Æ½Ã¾ÆÅÂÆò¾çÀº ÅÂ¾Æ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í °¡Ã³ºÐ ¼ÒµæÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¤±³ÇÑ ÅÂ¾Æ ¸ð´ÏÅ͸µ ±â±â¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ÀÌ Áö¿ª ½ÃÀå È®´ë¸¦ ÁÖµµÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀӽŠ°Ç¼ö Áõ°¡¿Í ÀÇ·á »ê¾÷ÀÇ ¹ßÀüµµ ½ÃÀå È®´ë¸¦ ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. Àα¸ Áõ°¡·Î ÀÎÇØ ÀÓ½ÅÇÏ´Â ¿©¼ºµéÀÌ ´Ã¾î³ª¸é¼­ ½ÃÀå È®´ë°¡ ¿¹»óµÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ¹ßÀü :

Áö³­ 5¿ù GEÇコÄɾî(¹Ì±¹)¿Í ÆÞ½¼¸ð¾î(À̽º¶ó¿¤)´Â ÆÞ½¼¸ð¾îÀÇ È¨Äɾî ÃÊÀ½ÆÄ ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­ÇÏ°í ¹Ì±¹ FDA ½ÂÀΰú »ó¾÷Àû È®ÀåÀ» ¸ñÇ¥·Î ÇÏ´Â ÆÞ½¼¸ð¾îÀÇ ¸ñÇ¥¸¦ Áö¿øÇϱâ À§ÇÑ °è¾àÀ» ü°áÇß½À´Ï´Ù.

2022³â 4¿ù, ArchiMed Group(ÇÁ¶û½º)Àº Natus Medical Incorporated(¹Ì±¹)¸¦ ÀμöÇÏ¿© ½ÃÀåÀ» ¼±µµÇÏ´Â Natus Á¦Ç°ÀÇ ¹üÀ§¿Í ÆøÀ» ³ÐÈ÷°í, ¿¬±¸°³¹ß¿¡ ÁýÁßÇÏ°í º¸¿ÏÀûÀÎ »ç¾÷ Àμö¸¦ ÃßÁøÇÒ °ÍÀÔ´Ï´Ù.

2022³â 3¿ù, Philips¿Í ´©º¸ ±×·ìÀº ÄÝ·Î¶óµµ ÁÖ ³óÃÌ Áö¿ª¿¡¼­ºÎÅÍ »êÀü°ü¸® ¼­ºñ½º Á¦°øÀ» È®´ëÇϱâ À§ÇØ Çù·ÂÇÕ´Ï´Ù. À̹ø Çù·ÂÀÇ ¸ñÀûÀº ³óÃÌ Áö¿ªÀÇ »ê¸ð °ü¸® °ÝÂ÷¸¦ ÇؼÒÇÏ°í °¡Á¤³» ¸ð´ÏÅ͸µÀ» ÅëÇØ ±ÔÁ¤µÈ »ê¸ð °ü¸®¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇÏ´Â °ÍÀÔ´Ï´Ù.

º¸°í¼­ ³»¿ë

  • Áö¿ª ¹× ±¹°¡º° ½ÃÀå Á¡À¯À² Æò°¡
  • ½Å±Ô ÁøÀÔ±â¾÷¿¡ ´ëÇÑ Àü·«Àû Á¦¾È
  • 2021³â, 2022³â, 2023³â, 2026³â, 2030³â ½ÃÀå µ¥ÀÌÅ͸¦ ´Ù·ì´Ï´Ù.
  • ½ÃÀå µ¿Çâ(ÃËÁø¿äÀÎ, ÀúÇØ¿äÀÎ, ±âȸ, À§Çù, °úÁ¦, ÅõÀÚ ±âȸ, ±ÇÀå»çÇ×)
  • ½ÃÀå ÃßÁ¤¿¡ ±â¹ÝÇÑ ÁÖ¿ä »ç¾÷ ºÎ¹®¿¡ ´ëÇÑ Àü·«Àû Á¦¾È
  • ÁÖ¿ä ÀϹÝÀû Æ®·»µå¸¦ ¸ÅÇÎÇÑ °æÀï ±¸µµ
  • »ó¼¼ÇÑ Àü·«, À繫 ¹× ÃÖ±Ù µ¿ÇâÀ» Æ÷ÇÔÇÑ ±â¾÷ °³¿ä
  • ÃֽŠ±â¼ú ¹ßÀüÀ» ¸ÅÇÎÇÏ´Â °ø±Þ¸Á µ¿Çâ

¹«·á Ä¿½ºÅ͸¶ÀÌÁ¦ÀÌ¼Ç ¼­ºñ½º :

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´¿¡°Ô´Â ´ÙÀ½ Áß ÇϳªÀÇ ¹«·á Ä¿½ºÅ͸¶ÀÌÁ¦ÀÌ¼Ç ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù.

  • ±â¾÷ °³¿ä
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀû ÇÁ·ÎÆÄÀϸµ(3»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(3»ç±îÁö)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ µû¸¥ ÁÖ¿ä ±¹°¡º° ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø, CAGR(ÁÖ : ½ÇÇö °¡´É¼º üũ¿¡ µû¸§)
  • °æÀï º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¿ªÀû ÀÔÁö, Àü·«Àû Á¦ÈÞ¿¡ ±â¹ÝÇÑ ÁÖ¿ä ±â¾÷ÀÇ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • ÁÖ¿ä ¿ä¾à
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç ¾îÇÁ·ÎÄ¡
  • Á¶»ç ¼Ò½º
    • 1Â÷ Á¶»ç Á¤º¸¿ø
    • 2Â÷ Á¶»ç Á¤º¸¿ø
    • ÀüÁ¦Á¶°Ç

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ÃËÁø¿äÀÎ
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • Á¦Ç° ºÐ¼®
  • ¾ÖÇø®ÄÉÀÌ¼Ç ºÐ¼®
  • ÃÖÁ¾»ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • COVID-19ÀÇ ¿µÇâ

Á¦4Àå Porters Five Force ºÐ¼®

  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷°£ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ ÅÂ¾Æ ¸ð´ÏÅ͸µ ½ÃÀå : Á¦Ç°º°

  • Àڱó»¾Ð Ä«Å×ÅÍ(IUPC)
  • ÅÚ·¹¸ÞÆ®¸® ¼Ö·ç¼Ç
  • ÃÊÀ½ÆÄ
    • µµÇ÷¯ À̹Ì¡
    • 3D¡¤4D ÃÊÀ½ÆÄ
    • 2D ÃÊÀ½ÆÄ
  • ¾×¼¼¼­¸®¿Í ¼Ò¸ðÇ°
  • ÅÂ¾Æ µµÇ÷¯
  • ÅÂ¾Æ Àü±Ø
  • ÀüÀÚ ÅÂ¾Æ ¸ð´ÏÅ͸µ(EFM)
    • ³»ºÎ EFM
    • ¿ÜºÎ EFM
  • ±âŸ Á¦Ç°

Á¦6Àå ¼¼°èÀÇ ÅÂ¾Æ ¸ð´ÏÅ͸µ ½ÃÀå : Æ÷Åͺô¸®Æ¼º°

  • ºñÈÞ´ë¿ë
  • ÈÞ´ë¿ë

Á¦7Àå ¼¼°èÀÇ ÅÂ¾Æ ¸ð´ÏÅ͸µ ½ÃÀå : ¹æ¹ýº°

  • ºñħ½À¼º
  • ħ½À¼º

Á¦8Àå ¼¼°èÀÇ ÅÂ¾Æ ¸ð´ÏÅ͸µ ½ÃÀå : ¿ëµµº°

  • ºÐ¸¸Àü
  • ºÐ¸¸½Ã
  • ±âŸ ¾ÖÇø®ÄÉÀ̼Ç

Á¦9Àå ¼¼°èÀÇ ÅÂ¾Æ ¸ð´ÏÅ͸µ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Áø·á¼Ò
  • º´¿ø
  • ÀçÅÃÀÇ·á
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦10Àå ¼¼°èÀÇ ÅÂ¾Æ ¸ð´ÏÅ͸µ ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîƼ³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Á¦ÈÞ, ÇÕº´»ç¾÷
  • ÀμöÇÕº´
  • ½ÅÁ¦Ç° Ãâ½Ã
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦12Àå ±â¾÷ °³¿ä

  • Cardinal Health
  • Natus Medical Incorporated
  • Siemens Healthineers
  • Koninklijke Philips N.V.
  • Neoventa Medical AB
  • OSI Systems, Inc.
  • Getinge AB
  • Analogic Corporation
  • GE Healthcare
  • ArchiMed Group
  • CONTEC Medical Systems Co.,Ltd.
  • Fujifilm Sonosite, Inc.
  • The Cooper Companies, Inc.
  • Bionet Co.,Ltd.
  • Trivitron Healthcare
  • DOTT Medical Co.,Ltd.
  • Edan Instruments, Inc.
  • GPC Medical Ltd.
KSA 23.08.09

According to Stratistics MRC, the Global Fetal Monitoring Market is accounted for $2.89 billion in 2023 and is expected to reach $4.96 billion by 2030 growing at a CAGR of 8.02% during the forecast period. A fetal monitoring system is a diagnostic tool used to monitor the mother's contractions as well as the fetus's movement and heart rate. It's a simple device for monitoring uterine contractions during labour. It mainly keeps an eye on the health of the foetus and how labour is going. In medical terms, it is defined to as a medical procedure to examine an unborn child in order to ensure a safe delivery.

According to The American College of Obstetricians and Gynecologists (ACOG), the demand for obstetrics and gynecology professionals is expected to increase from 50,850 to 52,660 (4%) by 2030.

Market Dynamics:

Driver:

Rising number of preterm births

Preterm births are becoming more common due to a number of factors, such as high blood pressure, prolonged pre-labour membrane rupture, antepartum haemorrhage, multiple gestations, assisted reproductive technology, short cervixes, urinary tract infections (UTIs), and placenta previa, among others. As preterm births, have become more common, advanced medical technology has been included into foetal monitoring systems, which is driving market expansion.

Restraint:

Availability of refurbished products

The availability of refurbished fetal monitoring instruments is the main barrier to this market's expansion. In developing nations, which are price-sensitive marketplaces, many small and medium-sized hospitals choose refurbished systems for cost effectiveness. All of these refurbished items offer the same functionality as new items but do so at a lesser price because of these factors. This issue would hurt the bottom line for businesses selling branded fetal monitoring products on the market.

Opportunity:

Rising number of government initiatives

The increase in government and non-government initiatives to raise awareness regarding foetal health is what is driving the market. A significant element affecting the market's growth will also be the increase in post-term pregnancy, multiple pregnancy, and premature birth instances. Additionally, the rise in changing lifestyles and rising infrastructure spending on healthcare are the main key drivers that will further accelerate the industry's expansion.

Threat:

Lack of skilled healthcare professionals

Obstetrics, gynaecology, and other preventative and reproductive healthcare specialists who focus primarily on women's health are in limited supply. This suggests that efforts in obstetrics and gynaecology may increasingly concentrate on managing high-risk pregnancies, difficult gynaecological diseases, and surgical treatments. But the expensive expense of foetal monitoring apparatus would slow the market's expansion.

COVID-19 Impact:

Fetal surveillance was among the businesses affected by the COVID-19 outbreak and the subsequent lockdown. Because treatments were postponed and rescheduled for safety reasons, there were fewer hospital patients during the pandemic, which contributed to a fall in the number of fetal monitoring procedures. A comprehensive review of the patient's medical history preceded these delays, and, where it was feasible, the timing of the fetal monitoring was changed to lessen the risk of exposure during hospital visits. This causes the pandemic to negatively affect the sector.

The ultrasound devices segment is expected to be the largest during the forecast period:

The ultrasound devices segment is estimated to have a lucrative growth. To study inside organs, an ultrasound device produces images. High-frequency sound waves are emitted by the apparatus, which the body's structures reflect. A computer detects the waves and utilises them to create a picture. Unlike an x-ray or a Computed Tomography (CT) scan, this diagnostic does not use ionising radiation. The images can be used for fetal monitoring as well as the diagnosis and planning of treatments for a wide range of illnesses and conditions.

The hospitals segment is expected to have the highest CAGR during the forecast period:

The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period, due to enhanced fetal monitoring devices provided by hospitals and availability of skilled physicians and infrastructure. The rise of the segment's revenue is being fueled by both the quantity of fetal monitoring devices installed in hospitals and the number of patients who visit the hospital for fetal monitoring.

Region with Largest share:

North America is projected to hold the largest market share during the forecast period, owing to the governments empowering small setups for healthcare research by bringing many countries. An increase in government support for improved maternal facilities, such as grants granted to private, non-profit organisations to expand care in rural areas in nations with underdeveloped healthcare infrastructure.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to growth in awareness about fetal monitoring and increase in disposable incomes. The increased demand for sophisticated fetal monitoring gadgets is what's driving this region's market expansion. In addition, a rise in the number of pregnancies and developments in the medical industry have helped the market expand. The market is therefore anticipated to rise as more women become pregnant as a result of the large population.

Key players in the market

Some of the key players profiled in the Fetal Monitoring Market include Cardinal Health, Natus Medical Incorporated, Siemens Healthineers, Koninklijke Philips N.V., Neoventa Medical AB, OSI Systems, Inc., Getinge AB, Analogic Corporationm, GE Healthcare, ArchiMed Group, CONTEC Medical Systems Co.,Ltd., Fujifilm Sonosite, Inc., The Cooper Companies, Inc., Bionet Co.,Ltd., Trivitron Healthcare, DOTT Medical Co.,Ltd., Edan Instruments, Inc. and GPC Medical Ltd.

Key Developments:

In May 2022, GE Healthcare (US) and Pulsenmore (Israel) signed an agreement to accelerate the adoption of Pulsenmore's home care ultrasound solutions and support their goal to pursue US FDA clearance and commercial expansion.

In April 2022, ArchiMed Group (France) acquired Natus Medical Incorporated (US) to expand the reach and breadth of Natus' market-leading products, reinforcing the focus on research & development and pursuing acquisitions of complementary businesses.

In March 2022, Philips and Nuvo Group collaborate to extend prenatal care delivery starting in rural Colorado. Collaboration aims to address maternal care disparities in rural areas and increase access to prescribed prenatal care via at-home monitoring.

Products Covered:

  • Intrauterine Pressure Catheter (IUPC)
  • Telemetry Solutions
  • Ultrasound
  • Accessories & Consumables
  • Fetal Doppler
  • Fetal Electrodes
  • Electronic Fetal Monitoring (EFM)
  • Others Products

Portability Covered:

  • Non-Portability
  • Portable

Methods Covered:

  • Non-Invasive
  • Invasive

Applications Covered:

  • Antepartum
  • Intrapartum
  • Other Applications

End Users Covered:

  • Clinics
  • Hospitals
  • Home Care Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Fetal Monitoring Market, By Product

  • 5.1 Introduction
  • 5.2 Intrauterine Pressure Catheter (IUPC)
  • 5.3 Telemetry Solutions
  • 5.4 Ultrasound
    • 5.4.1 Doppler Imaging
    • 5.4.2 3D & 4D Ultrasound
    • 5.4.3 2D Ultrasound
  • 5.5 Accessories & Consumables
  • 5.6 Fetal Doppler
  • 5.7 Fetal Electrodes
  • 5.8 Electronic Fetal Monitoring (EFM)
    • 5.8.1 Internal EFM
    • 5.8.2 External EFM
  • 5.9 Other Products

6 Global Fetal Monitoring Market, By Portability

  • 6.1 Introduction
  • 6.2 Non-Portability
  • 6.3 Portable

7 Global Fetal Monitoring Market, By Method

  • 7.1 Introduction
  • 7.2 Non-Invasive
  • 7.3 Invasive

8 Global Fetal Monitoring Market, By Application

  • 8.1 Introduction
  • 8.2 Antepartum
  • 8.3 Intrapartum
  • 8.4 Other Applications

9 Global Fetal Monitoring Market, By End User

  • 9.1 Introduction
  • 9.2 Clinics
  • 9.3 Hospitals
  • 9.4 Home Care Settings
  • 9.5 Other End Users

10 Global Fetal Monitoring Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Cardinal Health
  • 12.2 Natus Medical Incorporated
  • 12.3 Siemens Healthineers
  • 12.4 Koninklijke Philips N.V.
  • 12.5 Neoventa Medical AB
  • 12.6 OSI Systems, Inc.
  • 12.7 Getinge AB
  • 12.8 Analogic Corporation
  • 12.9 GE Healthcare
  • 12.10 ArchiMed Group
  • 12.11 CONTEC Medical Systems Co.,Ltd.
  • 12.12 Fujifilm Sonosite, Inc.
  • 12.13 The Cooper Companies, Inc.
  • 12.14 Bionet Co.,Ltd.
  • 12.15 Trivitron Healthcare
  • 12.16 DOTT Medical Co.,Ltd.
  • 12.17 Edan Instruments, Inc.
  • 12.18 GPC Medical Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦